Miles H. Linde

1.9k total citations · 1 hit paper
9 papers, 263 citations indexed

About

Miles H. Linde is a scholar working on Immunology, Oncology and Hematology. According to data from OpenAlex, Miles H. Linde has authored 9 papers receiving a total of 263 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Immunology, 3 papers in Oncology and 3 papers in Hematology. Recurrent topics in Miles H. Linde's work include CAR-T cell therapy research (3 papers), Immunotherapy and Immune Responses (3 papers) and Immune cells in cancer (3 papers). Miles H. Linde is often cited by papers focused on CAR-T cell therapy research (3 papers), Immunotherapy and Immune Responses (3 papers) and Immune cells in cancer (3 papers). Miles H. Linde collaborates with scholars based in United States, India and Australia. Miles H. Linde's co-authors include Ian L. Linde, Lei Shen, Edgar G. Engleman, Jingtao Qiu, Tyler R. Prestwood, Xiangyue Zhang, David Kung‐Chun Chiu, Wen‐Chao Song, Genay Pilarowski and Nathan E. Reticker-Flynn and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Investigation and Cancer Cell.

In The Last Decade

Miles H. Linde

8 papers receiving 259 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Neutrophil-activating therapy for the treatment of cancer

2023 117 citations Ian L. Linde, Tyler R. Prestwood et al. Cancer Cell profile →

Peers

Countries citing papers authored by Miles H. Linde

Since Specialization

Citations

This map shows the geographic impact of Miles H. Linde's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Miles H. Linde with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Miles H. Linde more than expected).

Fields of papers citing papers by Miles H. Linde

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Miles H. Linde. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Miles H. Linde. The network helps show where Miles H. Linde may publish in the future.

Co-authorship network of co-authors of Miles H. Linde

This figure shows the co-authorship network connecting the top 25 collaborators of Miles H. Linde. A scholar is included among the top collaborators of Miles H. Linde based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Miles H. Linde. Miles H. Linde is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

#	Work	Indexed citations
1	Immune evasion of dormant disseminated tumor cells is due to their scarcity and can be overcome by T cell immunotherapies 2024 ·Cancer Cell ·Erica T. Goddard, Miles H. Linde, Shivani Srivastava, (unknown), Tamer B. Shabaneh, (unknown), Candice Alexandra Grzelak, (unknown), Alessandra I. Riggio, Ryann E. Shor, Ian L. Linde, (unknown), Joshua Veatch, Annelise G. Snyder, Alana L. Welm, Stanley R. Riddell, Cyrus M. Ghajar	29
2	IDH1 -Mutant Preleukemic Hematopoietic Stem Cells Can Be Eliminated by Inhibition of Oxidative Phosphorylation 2023 ·Blood Cancer Discovery ·Niklas Landberg, Thomas Köhnke, Yang Feng, Yusuke Nakauchi, Amy C. Fan, Miles H. Linde, Daiki Karigane, Kelly Lim, Rahul Sinha, Luca Malcovati, Danièl Thomas, Ravindra Majeti	9
3	Reprogramming Cancer into Antigen-Presenting Cells as a Novel Immunotherapy 2023 ·Cancer Discovery ·Miles H. Linde, Amy C. Fan, Thomas Köhnke, Aaron C. Trotman-Grant, (unknown), (unknown), (unknown), Naomi L. Haddock, (unknown), Eric J. Gars, Melissa Stafford, Payton L. Marshall, Christopher G. Dove, Ian L. Linde, Niklas Landberg, (unknown), Robbie G. Majzner, Tian Yi Zhang, Ravindra Majeti	33
4	Neutrophil-activating therapy for the treatment of cancer breakdown → 2023 ·Cancer Cell ·Ian L. Linde, Tyler R. Prestwood, Jingtao Qiu, Genay Pilarowski, Miles H. Linde, Xiangyue Zhang, Lei Shen, Nathan E. Reticker-Flynn, David Kung‐Chun Chiu, (unknown), (unknown), Lorna Tolentino, Wen‐Chao Song, Edgar G. Engleman	117
5	AHR Regulates NK Cell Migration via ASB2–Mediated Ubiquitination of Filamin A 2021 ·Frontiers in Immunology ·June Ho Shin, (unknown), (unknown), Chen Chen, (unknown), Miles H. Linde, Emily M. Mace, John B. Sunwoo	24
6	Enasidenib drives human erythroid differentiation independently of isocitrate dehydrogenase 2 2020 ·Journal of Clinical Investigation ·(unknown), Tian Yi Zhang, Thomas Köhnke, Danièl Thomas, Miles H. Linde, Eric J. Gars, Melissa Stafford, (unknown), Yusuke Nakauchi, (unknown), Armon Azizi, Anupama Narla, Ravindra Majeti	21
7	Abstract PR07: GD2 is a macrophage checkpoint molecule and combined GD2/CD47 blockade results in synergistic effects and tumor clearance in xenograft models of neuroblastoma and osteosarcoma 2020 ·Cancer Research ·Johanna Theruvath, (unknown), Miles H. Linde, Elena Sotillo, Sabine Heitzeneder, Kristopher D. Marjon, Aidan M. Tousley, (unknown), Allison Banuelos, Shaurya Dhingra, Surya Murty, Crystal L. Mackall, Robbie G. Majzner	4
8	Reprogramming of primary human philadelphia chromosome-positive B cell acute lymphoblastic leukemia cells into nonleukemic macrophages 2016 ·Experimental Hematology ·Christopher G. Dove, Miles H. Linde, (unknown), Ravindra Majeti	0
9	Mechanistic Heterogeneity in Site Recognition by the Structurally Homologous DNA-binding Domains of the ETS Family Transcription Factors Ets-1 and PU.1 2014 ·Journal of Biological Chemistry ·(unknown), Miles H. Linde, Manoj Munde, (unknown), W. David Wilson, Gregory M.K. Poon	26

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact